Alpha 2.0
Login Register
» Authors » Thibault Mazard

Thibault Mazard

Explore the profile of Thibault Mazard including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 63
Citations 1152
Followers 0
Related Specialties
Oncology
Gastroenterology
General Medicine
Top 10 Co-Authors
Marc Ychou
Eric Assenat
Antoine Adenis
Emmanuelle Samalin
Alain R Thierry
Brice Pastor
Olivier Bouche
Thierry Andre
Julien Taieb
Fabienne Portales
Published In
Cancers (Basel)
Eur J Cancer
Clin Cancer Res
Sci Rep
EBioMedicine
Affiliations
Soon will be listed here.
Recent Articles
1.
Combined Analyses of Circulating Tumor DNA and Immunoscore in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France/HORG-IDEA-Greece Trials
Taieb J, Souglakos J, Boukovinas I, Falcoz A, Pages F, Messaritakis I, et al.
J Clin Oncol . 2025 Feb; :JCO2400648. PMID: 39903903
Purpose: Immunoscore (IS) and circulating tumor DNA (ctDNA) are two emerging technologies in improving prognostication and tailoring adjuvant treatments in patients resected from a stage III colon cancer (CC). Here,...
2.
Prognostic Models From Transcriptomic Signatures of the Tumor Microenvironment and Cell Cycle in Stage III Colon Cancer From PETACC-8 and IDEA-France Trials
Gallois C, Sroussi M, Andre T, Mouillet-Richard S, Agueeff N, Mulot C, et al.
J Clin Oncol . 2025 Jan; :JCO2302262. PMID: 39889251
Purpose: The objective of this work was to establish prognostic models in stage III colon cancer (CC) on the basis of transcriptomic signatures of the tumor microenvironment (TME) and cell...
3.
Early treatment discontinuation in patients with deficient mismatch repair or microsatellite instability high metastatic colorectal cancer receiving immune checkpoint inhibitors
Taieb J, Ambrosini M, Alouani E, Lonardi S, Sinicrope F, Decraecker M, et al.
J Immunother Cancer . 2025 Jan; 13(1. PMID: 39755579
Background: Immune checkpoint inhibitors (ICIs) are recommended to treat patients with deficient mismatch repair/microsatellite instability high (dMMR/MSI-H) metastatic colorectal cancer (mCRC). Pivotal trials have fixed a maximum ICI duration of...
4.
Post-surgery sequelae unrelated to disease progression and chemotherapy revealed in follow-up of patients with stage III colon cancer
Mirandola A, Kudriavtsev A, Cofre Munoz C, Navarro R, Macagno M, Daoud S, et al.
EBioMedicine . 2024 Sep; 108:105352. PMID: 39303668
Background: We studied the poorly-known dynamics of circulating DNA (cir-nDNA), as monitored prospectively over an extended post-surgery period, in patients with cancer. Methods: On patients with stage III colon cancer...
5.
Why Is Wnt/β-Catenin Not Yet Targeted in Routine Cancer Care?
de Pellegars-Malhortie A, Picque Lasorsa L, Mazard T, Granier F, Prevostel C
Pharmaceuticals (Basel) . 2024 Jul; 17(7). PMID: 39065798
Despite significant progress in cancer prevention, screening, and treatment, the still limited number of therapeutic options is an obstacle towards increasing the cancer cure rate. In recent years, many efforts...
6.
Regorafenib plus FOLFIRINOX as first-line treatment for patients with RAS-mutant metastatic colorectal cancer (FOLFIRINOX-R trial): a dose-escalation study
Adenis A, Ghiringhelli F, Gauthier L, Mazard T, Evesque L, Evrard A, et al.
Cancer Chemother Pharmacol . 2024 Jul; 94(3):443-452. PMID: 38987363
Purpose: The combination of bevacizumab and FOLFIRINOX is used in patients with RAS-mutant metastatic colorectal cancer (RASm-mCRC). Regorafenib, an oral multi-tyrosine kinase inhibitor, has antiangiogenic properties, cytostatic effects and also...
7.
Neoadjuvant radiotherapy combined with fluorouracil-cisplatin plus cetuximab in operable, locally advanced esophageal carcinoma: Results of a phase I-II trial (FFCD-0505/PRODIGE-3)
de Rauglaudre B, Piessen G, Jary M, Le Malicot K, Adenis A, Mazard T, et al.
Clin Transl Radiat Oncol . 2024 Jul; 47:100804. PMID: 38974185
Background: Radiotherapy combined with fluorouracil (5FU) and cisplatin for locally advanced esophageal cancer is associated with a 20-25% pathologic complete response (pCR) rate. Cetuximab increases the efficacy of radiotherapy in...
8.
Prognostic value of the tumor-to-liver density ratio in patients with metastatic colorectal cancer treated with bevacizumab-based chemotherapy. A post-hoc study of the STIC-AVASTIN trial
Mazard T, Mollevi C, Loyer E, Leger J, Chautard R, Bouche O, et al.
Cancer Imaging . 2024 Jun; 24(1):77. PMID: 38886836
Background: The Response Evaluation Criteria in Solid Tumors (RECIST) are often inadequate for the early assessment of the response to cancer therapy, particularly bevacizumab-based chemotherapy. In a first cohort of...
9.
Motor disorders related to oxaliplatin-induced peripheral neuropathy: long-term severity and impact on quality of life
Balayssac D, Kerckhove N, Selvy M, Pereira B, Gonneau C, Petorin C, et al.
Support Care Cancer . 2024 Jun; 32(7):427. PMID: 38869647
Purpose: Sensory chemotherapy-induced peripheral neuropathy (CIPN) is well-recognized, but motor CIPN remains understudied. This secondary analysis focused on the long-term severity and impact of motor disorders, their relation to sensory...
10.
A multicenter study evaluating efficacy of immune checkpoint inhibitors in advanced non-colorectal digestive cancers with microsatellite instability
Moreau M, Alouani E, Flecchia C, Falcoz A, Gallois C, Auclin E, et al.
Eur J Cancer . 2024 Mar; 202:114033. PMID: 38537314
Background: One randomized phase III trial comparing chemotherapy (CT) with immune checkpoint inhibitors (ICI) has demonstrated significant efficacy of ICI in deficient DNA mismatch repair system/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal...